Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease.
Schapira
Anthony H V
AH
University Department of Clinical Neurosciences, Royal Free and University College Medical School, UCL, Queen Square, London, United Kingdom. schapira@rfc.ucl.ac.uk
Olanow
C Warren
CW
D002986:Clinical Trials as Topic; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D018696:Neuroprotective Agents